Understanding the mechanism of fundraising rounds : from seed to Series C

💼 In brief — Raising funds is a decisive turning point for any startup seeking growth. From seed to Series C, each financing stage meets distinct needs and follows a well-defined progressive logic. Founders see their equity progressively diluted, investors demand increased governance rights, and legal complexity thickens at each round. Understanding this mechanism — valuation, shareholders' agreement, liquidation preference, anti-dilution — gives you the tools to negotiate without naivety and structure your financing without getting lost along the way.

📊 Key points to remember : A well-structured fundraising breaks down into five stages (Pre-Seed, Seed, Series A, B, C). Each phase brings increasing capital but also progressive dilution of your ownership. The pre-money valuation determines the percentage ceded to investors. The shareholders' agreement governs all rights and obligations. Liquidation preference and anti-dilution clauses can overwhelmingly favor investors. A rigorous due diligence avoids unpleasant surprises. Legal fees range between €10,000 and €60,000 depending on complexity. Finally, structuring with experts (lawyer, accountant) is not a luxury, it is a necessity.

🎯 The successive stages of financing: from seed to maturity

Imagine a startup as an ancient manuscript being prepared for binding. At first, a few scattered pages, a raw vision, doubts about the final format. Gradually, the work refines, signatures multiply, and the structure tightens. Each fundraising round resembles this gradual transformation — a passage from an informal state to an increasingly structured and regulated organization.

The financing of startups follows a logical progression in five acts. The first two (Pre-Seed and Seed) are experimental phases, where capital remains modest and investors are still little formalized. Then comes the turning point: Series A marks the arrival of true venture capital institutions, with all the legal complexity and return expectations that accompany them. Series B and C accelerate this dynamic, with exponential amounts and negotiations becoming almost diplomatic.

🌱 Seed: when everything starts with a conviction

At the Pre-Seed and Seed stage, a startup often has only a fragile prototype, a small team and a lot of passion. The capital raised — between €50,000 and €500,000 — exists only to validate the initial hypothesis: does the concept really work? Investors at this stage are business angels, specialized seed funds, or rare institutions willing to bet on the immaterial.

Initial dilution remains modest (10 to 20 %), but it already lays the foundations of future governance. At this stage, documents are often simple: a basic capital increase, some BSPCE for the first employees. The shareholders' agreement, if it exists, remains streamlined. It's a time of agility and trust, before lawyers overwhelm everything with cautious clauses.

🚀 Series A: the moment when everything accelerates

When commercial traction becomes tangible — first paying customers, measurable growth, product-market fit reached — Series A arrives. Amounts explode (€500,000 to €2 million), and above all, the players change. Venture capitalists and institutional investors massively enter the cap table, bringing not only checks but also a drastic demand for governance.

It is at this stage that the legal documentation becomes seriously complex. The shareholders' agreement becomes a 30 to 50-page document, stipulating board seats, liquidation preference mechanisms, anti-dilution clauses. Dilution accelerates: between 20 and 30 % of the capital can be ceded in a single operation. For founders, it's the moment when you go from owning 100% to 50–70%, which can be psychologically difficult.

📈 Series B and C: consolidation and hypergrowth

Series B and C are the consolidation phase. Your customers number in the hundreds or thousands, your team exceeds 50 people, your business model has proven viable. Amounts raised now approach €2 to €50+ million, attracting the largest funds and even strategic investors (other companies seeking a stake).

At this stage, exit expectations — a sale or an IPO — begin to dominate discussions. Investors no longer think solely about growth at all costs, but about their return on investment over a 5–7 year horizon. Anti-dilution clauses become major negotiation issues, because Series A investors fear a subsequent raise at a lower price (a “down round”). Your residual founder stake can now hover around only 20–30 %, but the company may now be worth €50–100 million.

Browse this detailed guide to the key stages of a fundraising to better grasp each transition between these critical phases.

💰 Valuation: the heart of the negotiation

Valuing a startup remains the most uncertain and contentious exercise of any fundraising. How do you assign a price to a company that has not yet reached profitability, whose future remains highly unpredictable? Yet this is the primary topic that animates any negotiation.

The pre-money valuation represents the value of your company before new capital arrives. The post-money valuation incorporates the capital raised. Concrete example: you raise €1 million with a pre-money valuation of €4 million; your post-money valuation becomes €5 million. The new investors therefore hold €1 million / €5 million = 20% of the capital. You, the founder who owned 100% before, now control only 80%.

📊 Valuation methods in practice

Investors never use a single method. They cross-check several approaches to validate their conviction. Comparables — analyzing the valuations of other similar startups that have recently raised — constitute the starting point. If your direct competitors raised at €8 million in Series A, you have a market indicator that's hard to ignore.

Revenue multiples work well for mature companies with stable turnover. For a startup still in exponential growth, this approach fails: you cannot reasonably value at 10 times revenue a company burning cash to acquire customers. Conversely, discounted cash flow requires forecasting your earnings over 5–10 years, which is more science fiction at this stage.

Remaining is the most subjective but often most influential method: market potential analysis. If you operate in a $10 billion market and think you can capture 10%, that justifies a $1 billion valuation. Attractive on paper, but not rigorous in practice. That's why seasoned investors mix all these approaches, leaving plenty of room for their intuition and confidence in the team.

⚖️ Overvaluing: a recurring trap

Many founders dream of an astronomical valuation, seeing each raise as validation of their genius. However, accepting an excessively high valuation creates a time bomb. Your investors will expect superhuman growth to justify that price. If you raise at $20 million in Series A but only triple your revenue the following year (which is already excellent), Series B investors will refuse to increase their valuation, generating a “down round.”

Worse: an artificially high valuation creates internal resentment. Your employees, told the company was worth $100 million after they joined, discover at Series B that it was actually worth only $50 million. Their options, supposedly lucrative, melt away. It's poison for team motivation and talent retention.

📋 Financing instruments: beyond simple equity

Raising funds does not necessarily mean selling ordinary shares. Financial structuring has become sophisticated, offering multiple instruments to meet distinct objectives. Each carries its advantages and risks, which is why expert advice becomes indispensable.

🔄 Classic capital increase: the royal road

The capital increase remains the most transparent and legally framed instrument. New shareholders bring money and become owners of new shares. It is simple, clear, and offers little surprise later. Contributions can take three forms: cash, contributions in kind (patents, real estate, equipment), or debt-to-equity swaps (creditors becoming shareholders).

This simplicity has a price: dilution occurs immediately and irreversibly. If you believe your company will be worth more in two years, selling shares today is a mistake. But if you're burning cash and need that injection immediately, no matter the future valuation — you need to breathe now.

📑 BSA and BSPCE: deferred dilution

Bons de Souscription d'Actions (BSA) offer an interesting alternative. The investor does not become a shareholder immediately, but acquires the right to become one at a future date and a defined price. Dilution is deferred, which can suit founders anxious to preserve control in an early phase.

BSPCE (Bons de Souscription de Parts de Créateur d'Entreprise) are a French creation, structured to encourage job creation in startups. They present significant tax advantages: exemption from social contributions for the employee, possible tax deduction for the company. But access is regulated: the company must meet the SME definition (fewer than 250 employees), and only employees, executives and certain contractors can benefit.

The trap of BSA and BSPCE: they will *inevitably* dilute capital upon exercise. Deferring them is borrowing time, not escaping dilution. It's tactically useful, but should not mislead about the economic reality.

🎯 Convertible bonds: hybrid and protective

Convertible bonds combine the best (and worst) characteristics of debt and equity. The investor is first a creditor, entitled to claim repayment of their loan with interest. But they can also convert this claim into shares at a defined date and price. This dual-track appeals to investors at a relative maturity stage: in case of startup failure, they at least recover something.

For the founder, this structure creates accounting ambiguity and documentary complexity. It is less dilutive in the short term than a capital increase, but becomes so in the long term. It adapts well to bridge raises, neither seed nor a true Series A.

💡 The SAFE: innovative instrument, fuzzy framework

The SAFE (Simple Agreement for Future Equity) is an instrument of American origin, increasingly used in France in very early phases. It's neither a share nor a debt, but simply an agreement allowing the investor to convert their contribution into shares during a subsequent raise or upon a triggering event (exit, IPO).

The major advantage: extreme documentary simplicity, few legal formalities. The major drawback: in France, the SAFE exists in a legal void. It could be requalified as a quasi-loan or as the creation of an annuity, with unpredictable tax consequences. Our recommendation: caution. If you opt for a SAFE, structure it with expert legal support; do not leave it administratively in limbo.

Discover how to structure your fundraising correctly to anticipate the pitfalls.

📜 Essential documents: the legal framework

A well-orchestrated fundraising relies on a precise documentary cascade. Each document serves a distinct purpose, and their omission or neglect can generate major conflicts later. Think of the structure of a traditional binding: each element — the cover, the signatures, the margins — must be perfectly coordinated, otherwise the work falls apart.

🔑 The term sheet: the roadmap

The term sheet (or sheet of terms) is the starting point of any serious operation. Although it is generally not legally binding (except for certain points like confidentiality), it sets out the main lines: amount raised, valuation, investment structure, governance rights, closing timetable. Think of the term sheet as a plan before building the complete legal edifice.

A solid term sheet includes the identification of investors and amounts, pre- and post-valuation, voting and board seat rights, protective clauses (liquidation preference, anti-dilution, drag-along, tag-along), conditions precedent and a detailed calendar. It is often accompanied by a letter of intent or confidentiality agreements to protect sensitive information exchanged.

✍️ The shareholders' agreement: constituting your shareholder base

If the term sheet is the first floor, the shareholders' agreement is the foundation. This contract between shareholders (founders and investors) sets out everything that matters: how decisions are made, what control rights each party has, under what conditions shares can be sold, how exits are managed (sale, IPO).

A typical shareholders' agreement includes investors' obligations (schedule for capital contributions), the company's obligations (financial transparency, regular reporting), governance rights (board representation, access to information), liquidity rights (drag-along and tag-along) and protection mechanisms (anti-dilution, preemptive rights).

This instrument is so critical that we recommend never neglecting it, even for a modest seed raise. Founders who omit it to “keep things simple” invariably end up with acute conflicts at the next raise, when investors discover the absence of clear rules. It's penny-wise, pound-foolish.

🔐 Representations and warranties: attesting to solidity

Every fundraising document requires founders and the company to make representations and warranties: statements certifying that the information provided is accurate and complete. These statements cover the legal situation (regular existence of the company, absence of hidden litigation), intellectual property (your patents, trademarks and software genuinely belong to you), regulatory compliance (GDPR, labor law compliance, etc.) and the absence of hidden liabilities.

The stakes are high: inaccurate representations expose directors to massive indemnities for fraud or damages. That's why a rigorous due diligence upstream — an internal legal audit — is essential before signing. Better to discover a problem yourself than to let it surface during investors' audits.

⚔️ Strategic clauses: where negotiations heat up

Beyond the basic documents, certain clauses crystallize power and fairness issues between founders and investors. These are the points that generate the most tension and where your legal support makes the difference between a balanced deal and a highly disadvantageous one.

🎁 Liquidation preference: who splits the cake in case of sale?

When your startup is sold, the money arrives. But who receives it first? Liquidation preference answers this question. It grants investors a priority right on proceeds. There are three variants: non-participating preferred (the investor recovers their initial contribution, then participates in the remainder like everyone else), fully participating preferred (they recover their contribution, then participate without cap — much more favorable to them) and capped participating (they recover their contribution, then participate up to a given multiple, for example 3x).

These clauses directly affect what you, the founder, take home. Example: you raise $1 million in Series A with a 1x non-participating liquidation preference. You sell the company for $5 million. The investor first takes $1 million, then participates in the remainder pro rata. If they hold 20% of the capital, they finally receive 1 + (4 × 20%) = $1.8 million. You and the other shareholders split the remaining $3.2 million. That's already less favorable for you. With a fully participating liquidation preference, the investor could receive $2.2 million. The difference is your money.

🛡️ Anti-dilution: the clause that creates tensions

Imagine you raised in Series A at $10 million. Then, 18 months later, business slows and you have to raise a Series B at a lower valuation, say $8 million (a “down round”). Series A investors, furious to see their investment devalued, activate an anti-dilution clause.

Weighted-average anti-dilution adjusts their price as if the weighted average of all raises were applied retrospectively. It's moderate. Full ratchet anti-dilution is brutal: it adjusts as if the Series A had taken place at the Series B price, automatically inducing massive dilution of the founders to compensate.

Example with full ratchet: Series A investors paid $10 per share. With a subsequent raise at $8, full ratchet anti-dilution retrospectively brings their price down to $8. Mathematically, the number of shares they control increases (since they paid less), diluting everyone, notably the founders. It's a punitive mechanism that weakens your position if the startup goes through a rough patch. Negotiate it imperatively.

🔗 Drag-along and tag-along: minority rights

The drag-along allows majority investors to force minorities to sell in a major transaction. It's a security for large investors: they know they will be able to sell 100% of their shares, without being stuck with a minority stake under a buyer they don't control.

The tag-along is the counterpoint: it gives minorities (founders, employees) the right to join the sale on the same terms. If investors sell at a good price, you can leave too. It's essential protection for minority founders, preventing them from being stuck in a structure they no longer control.

These two clauses are complementary and almost systematic in Series A and above. The real negotiation concerns details: at what transaction amount does drag-along trigger? Does tag-along apply also in the case of minority share sales, or only on control sales?

🔍 Due diligence: being scrutinized by investors

Once the term sheet is signed, the due diligence phase begins: the in-depth investigation conducted by investors (or their advisors) before releasing funds. This phase generally lasts 6 to 12 weeks and covers four dimensions: legal, financial, commercial and operational.

📁 Prepare your “data room”

Due diligence is organized around a “data room”: a centralized electronic folder containing all relevant documents. Imagine a fully digitized library that investors can consult at any time. Articles of association, customer contracts, commercial leases, insurance, intellectual property, litigation, consolidated accounts, patents — everything must be there.

A good data room must be organized logically, with clear indexes and quality documents (no poor scans, no corrupted files). It must also be “clean”: missing documents, documentary gaps, discrepancies between what was declared and what is produced raise red flags. That's why internal preparation — a prior legal audit — is essential.

🕵️ Internal legal audit: detect problems before investors

We strongly recommend a complete legal audit before approaching investors. It's about asking the same questions investors will ask: Have you complied with company formation formalities? Are your articles of association up to date? Is your intellectual property clearly cataloged and truly owned by you? Do you have poorly documented customer or supplier contracts? Is there latent litigation? Any unsatisfied tax obligations?

An internal audit means discovering your problems yourself, in confidentiality, and resolving them proactively. It costs between €5,000 and €20,000, depending on complexity. But it's an investment that pays off by avoiding shocks during investors' due diligence. Worse, it's better to have resolved a problem before their audit than to see it emerge during their investigation — at that point, you no longer control the narrative.

💼 Financial due diligence issues

Investors scrutinize your accounts with the eye of a tax inspector. They look for anomalies: invoices without justification, excessive or unjustified expenses, sudden revenue variations, hidden liabilities (unrecorded debts, contingent obligations). If your accounts do not “tell a good story,” they get worried.

It's also an opportunity for you to prepare credible forecasts for the next 3–5 years. Investors do not ask for a crystal ball, but for a reasoned model based on clear assumptions. If you forecast 200% growth next year, justify it: signing of large confirmed contracts? Planned marketing campaign? Launch of a new product with a clear addressable market?

📊 The mechanics of dilution: understand your residual stake

Dilution is mathematical and inevitable, but it remains psychologically hard for founders to accept. Going from 100% to 30% in a few years can feel like dispossession, even if the company has quintupled in value along the way. Understanding the mechanics helps to accept and manage it strategically.

🧮 Calculation and progression of dilution

Simple formula: after a capital raise, your percentage becomes (your shares) / (total shares post-raise). If you had 100% of 100 shares (total: 100 shares) and the company issues 50 shares sold to investors, you now control 100 / 150 = 66.7%. You have suffered a dilution of 33.3%.

This dilution accumulates with each raise. In Seed, you lose 15–20%. In Series A, another 20–25%. In Series B, 15–20%. In Series C, 10–15%. In total, after four raises, your cumulative stake falls from 100% to around 25–35%. It's normal — it's the cost of external growth. But you must anticipate and model it from the start.

🎯 Dilution mitigation strategies

Several tactics can limit the impact. First, anti-dilution mechanisms that protect you in case of a later raise at a lower price — but as seen, that creates other tensions. Then, BSPCE plans for the team must be sized prudently: offering too many options will also dilute your capital without bringing fresh money.

Finally, negotiating reasonable valuations at each stage avoids down rounds and therefore punitive anti-dilution. A prudent valuation in Series A, even if it irritates you, protects you if business slows temporarily. It's a balancing game between ambition and prudence.

💼 The French regulatory framework: navigating between the AMF and the tax authorities

Raising funds in France means navigating several legal regimes: the Code de commerce (capital increase), the Code monétaire et financier (public offering of securities), the Code du travail (BSPCE), and of course the requirements of the Autorité des Marchés Financiers and the tax administration.

📜 Public offering vs. private placement

A crucial distinction: a public offering (to more than 150 people or without audience limit) requires a prospectus approved by the AMF. A private placement (to a restricted number of informed investors) generally benefits from a prospectus exemption. Most startup raises operate as private placements for this reason: time and administrative cost savings.

However, exemption from a prospectus does not mean exemption from transparency. Placement documents must still contain materially accurate information, otherwise you expose the company to criminal prosecution and directors to personal liability. It's a balance: administrative simplicity but informational rigor.

💡 Crowdfunding: a legitimate alternative?

Equity crowdfunding — raising from individual contributors via authorized platforms — is regulated in France and enjoys some popularity among startups seeking visibility. Advantages: community building, market validation, media coverage. Disadvantages: many small shareholders difficult to manage later, potential conflicts during subsequent rounds.

Crowdfunding works better as a complement to a traditional raise, not as the sole source of financing. Raise €500,000 from institutional investors and €200,000 via crowdfunding — that's strategically solid. Raise €700,000 entirely via crowdfunding with an inexperienced team — that's taking a significant risk.

⏰ Typical timeline of a raise: from dream to reality

A well-structured fundraising follows a predictable timeline, even though variations always exist. Understanding this timeline helps plan your year and internal resources.

🚀 The four phases in detail

Weeks 1–4: Preparation and sourcing — You prepare your pitch deck, your investor file, a clear presentation of your key metrics. You identify target investors (funds specialized in your sector and stage), and you start initial calls. This phase is mostly internal work, with little external cost.

Weeks 4–8: Term sheet negotiation — You discuss with one or more lead investors. Exchanges focus on valuation, amount, structure (equity, BSPCE, convertible instruments). A non-binding term sheet is signed to fix terms. This phase is the most political: it's where you really negotiate.

Weeks 8–16: Due diligence — You provide your data room, answer hundreds of questions, organize meetings between the investor's advisors (lawyers, accountants, consultants) and your team. It's intense but necessary. This phase reveals latent problems your internal audit should have detected.

Weeks 16–24: Final documentation and closing — Signing of final documents (shareholders' agreement, capital increase, statutory amendments), approval by the general meeting, filing with the clerk, final release of funds. At this stage, everything is in place; it's the necessary bureaucracy.

This timeline can be shortened to 8–10 weeks for a simple raise (seed from a single investor) or extended to 6 months for a complex Series C with in-depth due diligence and multiple investors.

👥 Key players: who pays for what?

A well-orchestrated raise involves several professionals. Each brings a distinct angle, and omitting one of them in the hope of “keeping things simple” invariably creates costly problems later.

⚖️ The corporate lawyer: your legal safeguard

A lawyer specialized in startup financing brings considerable value: optimal structuring of the financial instrument, negotiating terms with investors, drafting core documents, preparing for due diligence, managing legal formalities and regulatory compliance. Their cost for a Series A? Between €8,000 and €20,000, about 1–2% of the amount raised. It's a worthwhile investment.

💰 The accountant: financial and tax validation

An accountant usefully complements the lawyer by validating the valuation, checking the quality of the accounts, optimizing the tax treatment of the transaction (taxation of investors, possible deductions, accounting treatment). They also help prepare credible financial forecasts to present. Their cost: €3,000 to €10,000, depending on complexity. Together, lawyer + accountant form a minimal team for a serious raise.

🔍 The commissioner for contributions: valuing non-cash contributions

If you raise via contributions in kind (patents, real estate, equipment), a commissaire aux apports must evaluate the contribution and draft a report. It's a legal requirement for SAs and a recommended minimum for SASs. Their cost: €2,000 to €5,000. It's a modest investment to secure the operation and avoid later contestation of the value attributed to your contributions.

🎓 Structure without naivety: final recommendations

Raising funds is a critical step but navigable. With the right experts and meticulous preparation, you turn what could be a chaotic process into an ordered and profitable progression. Key points: invest in legal and accounting support from the start, anticipate dilution and negotiate it lucidly, prepare scrupulously for investors' due diligence, understand every clause before signing (liquidation preference, anti-dilution, drag-along, tag-along), and never neglect the shareholders' agreement even for a modest seed raise.

Also browse this practical guide to the main fundraising terms to complete your understanding of the specialized vocabulary.

Well-mastered fundraising is not dispossession, it's a controlled transfer. You cede ownership, but in exchange you capture capital, expertise and prestige that accelerate your ascent. It's an exchange where, if you negotiate well, everyone wins.